Paige
Paige is a computational-pathology company spun out of Memorial Sloan Kettering Cancer Center. Its software analyses digitised tissue slides to assist cancer diagnosis, and it received the FDA's first clearance for an AI product in pathology, Paige Prostate (2021). In August 2025 Paige agreed to be acquired by Tempus AI for approximately $81.25 million, paid primarily in Tempus stock.
- Founded
- 2017
- Headquarters
- New York, US
- Founders
- Thomas Fuchs
- Status
- Acquired by Tempus AI (announced August 2025, ~$81.25M, primarily stock)
- Latest round
- Series C, $100M (2021)
- Key investors
- Goldman Sachs, Casdin Capital, Memorial Sloan Kettering (shareholder)
- Category
- Medical imaging AI
- Products
- Paige Prostate, FullFocus digital pathology viewer
- Website
- www.paige.ai
Covered in: Artificial Intelligence in Healthcare
Sources
Profile compiled from the public sources listed above. Funding, valuation, and employee figures are point-in-time and may be out of date.